Investment Rating - The investment rating for the company is "Buy" (maintained) [1][2] Core Insights - The company has made a strategic move in the nuclear fusion sector by partnering with Huazhong University of Science and Technology to focus on key technologies such as plasma disruption prediction systems and mitigation techniques [2][4] - The company maintains its profit forecasts for 2025-2027, expecting net profits of 602 million, 656 million, and 707 million yuan respectively, with corresponding EPS of 0.77, 0.84, and 0.90 yuan [2][5] - The current stock price corresponds to a PE ratio of 20.2, 18.6, and 17.2 for the years 2025-2027, indicating a favorable valuation as the company expands into new business areas [2][5] Financial Summary - Revenue projections for 2025-2027 are 4.798 billion, 5.055 billion, and 5.413 billion yuan, with year-over-year growth rates of 6.6%, 5.4%, and 7.1% respectively [5][6] - The gross margin is expected to improve from 27.2% in 2025 to 28.0% in 2027, while the net profit margin is projected to increase from 12.5% to 13.1% over the same period [5][7] - Return on equity (ROE) is forecasted to rise from 10.3% in 2025 to 10.5% in 2027, reflecting improved profitability [5][6]